Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

This study has been completed.
Astellas Pharma Taiwan, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: November 23, 2009
Last updated: January 28, 2016
Last verified: January 2016
To compare the safety and efficacy of Prograf® with Myfortic® to Advagraf® extended release tacrolimus with Myfortic® in de novo liver transplant recipients.

Condition Intervention Phase
Liver Transplantation
Drug: Prograf
Drug: Advagraf
Drug: Myfortic
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus)/ Myfortic® and Advagraf® (Extended Release Tacrolimus) / Myfortic® in de Novo Liver Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Incidence of biopsy confirmed acute rejection [ Time Frame: during the 6 months post-transplant. ]

Secondary Outcome Measures:
  • Patient and graft survival rates [ Time Frame: during the 6 months post-transplant ]
  • Time to first biopsy confirmed acute rejection episode [ Time Frame: during the 6 months post-transplant ]
  • Incidence of anti-lymphocyte antibody therapy for treatment of rejection [ Time Frame: during the 6 months post-transplant. ]
  • Safety assessed by adverse events, laboratory parameters, physical examinations and vital signs [ Time Frame: throughout the study ]

Enrollment: 44
Study Start Date: April 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Prograf with Myfortic Drug: Prograf
Other Names:
  • Tacrolimus
  • FK506
Drug: Myfortic
Other Name: Mycophenolate sodium
Experimental: Advagraf with Myfortic Drug: Advagraf
Other Names:
  • Extended release tacrolimus
  • FK506E
  • MR4
Drug: Myfortic
Other Name: Mycophenolate sodium


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is a primary liver transplant recipient
  • Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to transplant
  • Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures
  • Patient must receive 1st dose of study drug within 24 hours of pre-transplantation

Exclusion Criteria:

  • Patient has previously received or is receiving an organ transplant other than a liver
  • Patient currently requires dialysis
  • Patient has received a liver transplant from a non-heart beating donor
  • Patient has received an ABO incompatible donor liver
  • Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
  • Patient has fulminant hepatic failure, unless hemodynamically stable
  • Patient has an uncontrolled concomitant infection, a systemic infection requiring treatment (except viral hepatitis), or any other unstable medical condition that could interfere with the study objectives
  • Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant
  • Patient has a known hypersensitivity to tacrolimus, enteric-coated mycophenolate sodium or corticosteroids
  • Patient is pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01018914

Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT01018914     History of Changes
Other Study ID Numbers: ADVLTx-0901-TW
Study First Received: November 23, 2009
Last Updated: January 28, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on April 21, 2017